Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite
outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with
recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional
outcomes as measured by the modified Rankin Scale.
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)